Provided by Tiger Fintech (Singapore) Pte. Ltd.

Johnson & Johnson

155.21
+0.62500.40%
Volume:1.42M
Turnover:220.06M
Market Cap:373.43B
PE:17.27
High:155.81
Open:155.41
Low:153.83
Close:154.58
Loading ...

BUZZ-Insulet rises after co names new CEO, signals improved rev outlook

Reuters
·
17 mins ago

Insulet Appoints Ashley McEvoy President and CEO

Business Wire
·
5 hours ago

Johnson & Johnson : HSBC Raises Target Price to $184 From $180

THOMSON REUTERS
·
9 hours ago

Johnson & Johnson announces new data from Cohort 2 of Phase 2b SunRISe-1

TIPRANKS
·
17 hours ago

Jim Cramer Says You Should Buy Johnson & Johnson (JNJ), Thinks Talc Problems ‘Behind It’

Insider Monkey
·
19 hours ago

BRIEF-Johnson & Johnson's Tar-200 Monotherapy Demonstrates Highest Complete Response Rate With Sustained Clinical Benefits In Patients With Certain Types Of Bladder Cancer

Reuters
·
Yesterday

Johnson & Johnson - Initiates FDA Application for Tar-200 Under Rtor Program

THOMSON REUTERS
·
Yesterday

Johnson & Johnson's Tar-200 Monotherapy Demonstrates Highest Complete Response Rate With Sustained Clinical Benefits in Patients With Certain Types of Bladder Cancer

THOMSON REUTERS
·
Yesterday

Johnson & Johnson - Phase 2B Study: 82% Achieve Complete Response, 52.9% Cancer-Free at One Year

THOMSON REUTERS
·
Yesterday

Johnson & Johnson - Tar-200 Potential to Transform Outcomes for Bcg-Unresponsive Bladder Cancer

THOMSON REUTERS
·
Yesterday

Johnson & Johnson's TAR-200 monotherapy demonstrates highest complete response rate with sustained clinical benefits in patients with certain types of bladder cancer

PR Newswire
·
Yesterday

These 2 Top Dividend Stocks Are Making Moves to Avoid the Impact of Tariffs: Are They Buys?

Motley Fool
·
26 Apr

Is Johnson & Johnson (JNJ) the Best Safe Stock to Buy According to Hedge Funds?

Insider Monkey
·
26 Apr

Loeb's Third Point builds stake in Band-Aid maker Kenvue

Reuters
·
26 Apr

Market Chatter: Third Point Capital Builds Stake in Kenvue

MT Newswires Live
·
26 Apr

Another drugmaker says tax reform, not tariffs, would drive U.S. manufacturing

Dow Jones
·
26 Apr

Amgen to expand Ohio biotech manufacturing plant

Reuters
·
26 Apr

Market Chatter: Report Says 25% Pharma Tariff Would Raise US Drug Costs by $51 Billion Annually

MT Newswires Live
·
25 Apr

Report Says 25% Pharma Tariff Would Raise US Drug Prices by $51 Billion Annually, Reuters Reports

MT Newswires Live
·
25 Apr

Dow's 117-Point Drop Led By Losses In Merck, Verizon Shares

Dow Jones
·
25 Apr